AbbVie Shares Slide After Q2 Results, Guidance Miss Sparks Profit-Taking
AbbVie shares fell sharply in pre-market trading after the company released second-quarter 2026 results and reiterated guidance that came in below Wall Street expectations. A previously disclosed $291 million IPR&D and milestones charge that trims EPS by $0.17 per share, combined with adjusted Q2 EPS guidance beneath consensus, prompted a class…